Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.80 |
| ▸ | MMP13 | P45452 | 20/20 | 0.80 |
| ▸ | MMP2 | P08253 | 1/20 | 0.72 |
| ▸ | MMP3 | P08254 | 1/20 | 0.72 |
| ▸ | MMP9 | P14780 | 1/20 | 0.72 |
| ▸ | MMP8 | P22894 | 1/20 | 0.72 |
| ▸ | MMP12 | P39900 | 1/20 | 0.72 |
| ▸ | MMP14 | P50281 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208011 | 1.00 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL12076481 | 1.00 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5139159 | 0.98 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208072 | 0.93 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7209156 | 0.93 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL2575324 | 0.93 | MMP1 (0.79) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5914587 | 0.91 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL135680 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208581 | 0.89 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7213054 | 0.89 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473271-A1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3135692-B1 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3135692-A1 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2582727-B1 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE | UNIV PITTSBURGH (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2796468-A2 | Antibodies to insulin-like growth factor I receptor | Pfizer Inc (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2275446-A2 | Antibodies to insulin-like growth factor I receptor | Pfizer Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2194067-A2 | Antibodies to insulin-like growth factor I receptor (IGF-IR) | PFIZER INC. (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1399483-B1 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR | PFIZER (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-1181285-B1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1181285-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6342521-B1 | DRUGS FOR TREATMENT OF ARTHRITIS | PFIZER INC. | 2002-01-29 | — | — | US | disclosed |
| WO-2000073294-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | disclosed |